GB202102488D0
|
|
Treatment
|
GB202102410D0
|
|
Treatment
|
GB202102408D0
|
|
Formulation
|
GB202016274D0
|
|
Formulation
|
GB202016289D0
|
|
Treatment
|
GB202012719D0
|
|
Novel antibacterial compounds
|
GB202010575D0
|
|
Treatment
|
GB202010573D0
|
|
Formulation
|
GB202005340D0
|
|
Formulation
|
GB202004844D0
|
|
Treatment
|
WO2020148271A1
|
|
Modified release tablet formulations containing phosphodiesterase inhibitors
|
WO2020089467A1
|
|
Dosage regimen
|
WO2020089470A1
|
|
Halogenated salicylanilides for treating the symptoms of dermatitis
|
GB201911526D0
|
|
Novel antibacterial compounds
|
WO2020091804A1
|
|
Treatment of inflammatory conditions
|
CN109715150A
|
|
Combination including dibromo propamidine or diminazene and tetracycline antibacterial agent
|
US2019151231A1
|
|
Non-aqueous topical compositions comprising a halogenated salicylanilide
|
EP3302492A1
|
|
Halogenated salicylanilides for treating clostridium infections
|